.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,754,109

« Back to Dashboard

Claims for Patent: 8,754,109

Title:Pirfenidone therapy and inducers of cytochrome P450
Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Inventor(s): Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee: Intermune, Inc. (Brisbane, CA)
Application Number:13/513,472
Patent Claims: 1. A method of increasing the effectiveness of pirfenidone therapy by avoiding decreased exposure to pirfenidone, in a patient in need of pirfenidone therapy and taking a strong inducer of cytochrome P450 1A2 (CYP1A2), comprising administering to the patient a therapeutically effective amount of pirfenidone, and avoiding the strong inducer of a cytochrome P450 1A2 (CYP1A2).

2. The method of claim 1, wherein the patient has idiopathic pulmonary fibrosis.

3. The method of claim 1, wherein the patient suffers from a fibrosis condition.

4. The method of claim 1, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

5. The method of claim 2, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

6. The method of claim 1, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

7. The method of claim 2, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

8. The method of claim 1, wherein each dose of pirfenidone administered is 801 mg.

9. The method of claim 6, wherein pirfenidone is administered three times a day.

10. The method of claim 9, wherein pirfenidone is administered with food.

11. The method of claim 1, wherein the strong CYP1A2 inducer is cigarette smoke.

12. The method of claim 11, wherein the patient has idiopathic pulmonary fibrosis.

13. The method of claim 11, wherein the patient suffers from a fibrosis condition.

14. The method of claim 11, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

15. The method of claim 12, wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

16. The method of claim 11, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

17. The method of claim 12, wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

18. The method of claim 16, wherein pirfenidone is administered three times a day.

19. The method of claim 18, wherein pirfenidone is administered with food.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc